This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Clinical trial news burned a few biotech stocks Thursday, while brighter trial updates kept others on higher ground.

NPS Pharmaceuticals (NPSP) gave up $1.50, or 27%, to $4.17 after its drug for short bowel syndrome failed to meet its goal in a phase III study. Specifically, the goal was a reduction in parenteral nutrition (being fed intravenously) of at least 20%.

The lower-dose group did show a statistically significant reduction compared with placebo, but according to the study design, the high-dose group needed to show statistical significance before the results for the low-dose group could be considered. The company said it will meet with the Food and Drug Administration to discuss the results.

Also, CuraGen (CRGN) said its velafermin for the prevention of mouth ulcerations in patients undergoing chemotherapy treatment failed a phase II clinical trial, and it is discontinuing its development. The company is now focusing on belinostat in phase II clinical trials for solid tumors and malignancies. Shares fell 48 cents, or 33%, to 98 cents.

NPS and CuraGen both tugged at the Nasdaq biotechnology index, which was down $2.15, or 0.2%.

Small-cap Cortex Pharmaceuticals (COR - Get Report) crashed after reporting that the FDA sent a final rejection to the company's investigational new-drug application (IND) to study its CX717 in a Phase IIb study in attention deficit hyperactivity disorder, based on results of animal toxicology studies that Cortex filed.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
NPSP $45.97 0.02%
NOVC $0.33 0.00%
ARIA $9.71 0.00%
COR $50.35 0.00%
MNTA $20.13 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs